Please login to the form below

Sutent

This page shows the latest Sutent news and features for those working in and with pharma, biotech and healthcare.

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

In June, Merck and Eisai also announced that the Keytruda plus Lenvima combination treatment improved outcomes when compared to Pfizer’s Sutent (sunitinib) on a measure of health-related quality of ... Previously, Merck and Eisai reported that Keytruda

Latest news

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Novartis’ Afinitor (everolimus) versus Sutent (sunitinib) for the first-line treatment of advanced RCC patients. ... time to first deterioration (TTD) for physical functioning, dyspnea, appetite loss and the EQ-5D visual analog scale compared to Sutent.
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Twice as many patients responded to Opdivo plus Cabometyx compared to Sutent – 55.7% and 27.1%, respectively. ... Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9% with Sutent.
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

In this trial, Keytruda plus Lenvima demonstrated superior efficacy benefits compared with Sutent. ... Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9% with Sutent.
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

BMS/Exelixis’ combination treatment doubled median PFS compared to Sutent, and also demonstrated a 34% reduction in the risk of death compared to Pfizer’s drug. ... Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9%
BMS gains FDA approval for second Opdivo combo in kidney cancer

This approval is based on results from the phase 3 CheckMate-9ER trial, which compared Opdivo plus Cabometyx to Pfizer’s older tyrosine kinase inhibitor (TKI) Sutent (sunitinib) in patients with ... In addition, the overall response rate (ORR) for

More from news
Approximately 3 fully matching, plus 84 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent.
Charting a course for expansion

In addition to meeting the primary endpoint of the study, the trial also showed median progression-free survival of 8.2 months versus Sutent's 5.6 months.
Intellectual property threats in the BRIC markets

of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.
Building BRICs: pharma's key emerging markets are becoming giants

This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV) and Pfizer's Sutent (cancer).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Cipla appoints Novartis’ Subhanu Saxena as CEO

The verdict followed another recent win, that this time saw it granted permission to market a generic version of Pfizer's Sutent (sunitinib malate) after challenging the drug's patent.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... This meant that due to lack of data, there was no benefit found for

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Omnichannel Account Director: £55,000 - £65,000 yearly

Technical Sales Representative: Highly competitive salary

Strategy Director - Healthcare Advertising: £90,000 - £120,000 yearly

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Pharmacovigilance Project Lead: Highly competitive salary

Senior Medical Writer: Highly competitive salary

Associate Director - Global Healthcare Consulting: £100,000 - £115,000 yearly

Pharmacovigilance Manager: Highly competitive salary

PMHub

Add my company

Anthem PR

With a rare strength in media and influencer relations, Anthem’s award-winning team offers a fresh approach to health PR...

Latest intelligence

The speed of science and the pace of comms: Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness: Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......

Email:
Password:

Please login to the form below

Sutent

Subscribe to our email news alerts

Quick links